TUC general secretary PAUL NOWAK speaks to the Morning Star’s Berny Torre about the increasing frustration the trade union movement feels at a government that promised change, but has been too slow to bring it about
Public pharma v abusive prices: the case of the latest HIV-prevention drug
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production
An electron micrograph of HIV-1 virus particles (colourized red) replicating from an HIV-infected H9 T-cell (blue)
DIANE ABBOTT exposes the misconceptions, rumours and downright lies perpetrated around immigration issues
With 12,000 fewer teachers since 2010 and dwindling resources, Scotland’s schools desperately need investment to support diverse learners rather than empty promises from politicians, writes ANDREA BRADLEY
Reversing outsourcing is the pre-election promise the government must honour, says Unison general secretary CHRISTINA McANEA
EMAN ABU ZAYED reminisces about the perilous time her family and neighbours endured in northern Gaza and how they were forced, in fear of their lives, to flee south
The EIS president who defended Marxist politics in the 1980s fought Thatcherite educational policies while organising Teachers for Peace rallies and ensuring Morning Star circulation in Scotland’s pit villages and factories, writes JOHN FOSTER
LENACAPAVIR, an injectable antiretroviral drug developed by Gilead Sciences, recently made headlines after a Phase 3 clinical trial in South Africa and Uganda showed it to be 100 per cent effective in preventing HIV among women and adolescent girls.
Though hailed as a breakthrough in HIV prevention, lenacapavir serves as a stark reminder of the problems with the pricing of life-saving medicines.
While further data from this study and results from studies involving other populations are needed, lenacapavir could be considered the most durable HIV prevention method to show efficacy among women — a population for who biomedical HIV prevention evidence has been severely limited.
Similar stories
When privatisation is already so deeply embedded in the NHS, we can’t just blindly argue for ‘more funding’ to solve its problems, explain ESTHER GILES, NICO CSERGO, BRIAN GIBBONS and RATHI GUHADASAN
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
Labour’s controversial plan to put the overweight and unemployed on the ‘skinny jab’ Mounjaro should set alarm bells ringing once we look into some of the research into the drug and the company set to supply it, warns CLAUDIA WEBBE
Keep Our NHS Public campaigner GREG DROPKIN dissects how Lord Darzi’s recommendations align with Starmer’s plans for NHS ‘reform,’ warning of creeping privatisation under the guise of modernisation